

9. Essential features. How the unique features, characteristics, or capabilities are essential for the agency to accomplish its work: Our current system allows us to use both individual nucleic acid assays and a dual kinetic design which allows for the simultaneous detection and identification of both Chlamydia trachomatis and Neisseria gonorrhoeae. All other FDA approved test kits require the performance of individual assays or detection procedures to achieve this result. These products are also approved for a longer specimen transport and storage period of time than the other products. All other known products require testing within 7 days of collection and these products allows the specimen to be tested, if stored properly, up to 60 days after collection. This property is an essential consideration, especially with the transport times from neighbor island facilities. The availability of a urine transport system, which will reduce the possibility of cross contamination, also provides the ability to test non invasive specimens. This will allow for the testing of patients from areas where the collection of specimens requiring invasive procedures is not available. (continued on attached sheet)

11. Alternate source. The following other possible sources for the good, service, or construction were investigated but do not meet our needs because: No other manufacturer is able to provide this technology. Individual nucleic acid assays from other manufacturers and Gen-Probe have been reviewed and found to be too labor intensive and costly to implement. The specimen transport times for all other FDA approved products are limited to 7 days from date of collection. The current equipment is only compatible with reagent test kits using the Gen-Probe Aptima technology.


12. Direct any inquiries to:
 Department: Health
 Contact Name/Title: Gail Y. Kunimoto/Chief, Medical Microbiology

13 Phone Number:
453-6700
 Fax Number:
453-6716

Expenditure may be processed with a purchase order: Yes No If no, a contract must be executed and funds certified.

Agency shall ensure adherence to applicable administrative and statutory requirements.

14 I certify that the information provided above is to the best of my knowledge, true, correct and that the goods, services, or construction are available through only one source.



FEB 27 2008

Department Head

Date

Reserved for SPO Use Only

15 Date Notice Posted: 2/29/08

Submit written objections to this intent to issue a sole source contract within seven calendar days or as otherwise allowed from the above posted date to: Chief Procurement Officer
 State Procurement Office
 P.O. Box 119
 Honolulu, Hawaii 96810-0119

16. Chief Procurement Officer's comments:

17.

APPROVED DISAPPROVED NO ACTION REQUIRED

Adrian S. Fajal 3/7/08
Chief Procurement Officer Date

REQUEST FOR SOLE SOURCE

Laboratory Test Kits Based on Nucleic Acid Amplification, Target Capture and Dual Kinetic Assay

February 21, 2008

Page 2

8. The good, service, or construction has the following unique features, characteristics or capabilities: (continued)

The dual kinetic assay allows for the detection of both *Chlamydia trachomatis* and *Neisseria gonorrhoeae* on one test run. This is accomplished through the use of dissimilar kinetic detection systems. This dual system reduces the amount of time compared with the requirement of conducting assay methods specific for these agents. In essence, this one procedure allows the detection or absence and identification of both agents, without additional testing. Since the test is based on unique genetic properties of the organisms, no additional confirmatory testing is required.

No other test kits are compatible with our instrumentation.

9. Essential Features. How the unique features, characteristics, or capabilities are essential for the agency to accomplish its work. (continued)

These products are also the only known FDA approved products that allow for testing of patient and physician collected vaginal specimens, female and male urine specimens, in addition to female endocervical and male urethral specimens. This will allow the Department's control program to evaluate the incidence of disease in geographic areas that have not been tested.